$115 Million Judgment Against Illumina
higher than the royalty rate found by the jury. The patent expires in October 2019. Illumina did not issue a statement.
The court granted Syntrix’s motion for a higher royalty rate for ongoing infringement, but ruled in favor of Illumina in determining that royalties should be calculated based on products shipped, rather than product orders. In addition to the verdict amount of $96 million, the award included $7 million in prejudgment interest and $12 million in supplemental damages.
Auburn, WA 6/20/13; Tacoma, Washington 6/18/13—Syntrix Biosystems has announced a final judgment of $115 million in its 2010 patent infringement case against Illumina in the US District Court for the Western District of Washington (see IBO 4/30/11). In March, a jury found Illumina guilty of infringing US Patent No. 6,951,682 covering synthetic matrix and array technology by selling BeadChip products, and ordered the company to pay $96 million in damages (see IBO 3/31/13). In the latest ruling, the court ordered additional damages related to Illumina’s infringing sales from May 2012 through March and prejudgment interest from 2005. Syntrix stated that Illumina will pay it at a royalty rate of 8% on continuing sales of the products, which is 2%
